Exkivity Withdrawal Is Blow To Takeda’s Oncology Ambitions

The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.

Takeda is to withdraw Exkivity, its treatment for EGFR Exon20 insertion mutation-positive non-small cell lung cancer, from the US and other markets after it failed to show its value over standard chemotherapy in a Phase III confirmatory trial.

The oral tyrosine kinase inhibitor gained an accelerated US marketing approval in September 2021, based on Phase I/II trial results...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip